ArticleCells2020
BE4max and AncBE4max Are Efficient in Germline Conversion of C:G to T:A Base Pairs in Zebrafish.
Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Rationally Designed TadA-Derived Cytosine Editors Enable Context-Independent Zebrafish Genome Editing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Optimized Ribonucleoprotein Complexes Enhance Prime Editing Efficiency in Zebrafish.Animals : an open access journal from MDPI · 2025Article
- Sequence Context-Agnostic TadA-Derived Cytosine Base Editors for Genome-Wide Editing in Zebrafish.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Base editors in zebrafish: a new era for functional genomics and disease modeling.Frontiers in genome editing · 2025Review
- Cytosine base editors with increased PAM and deaminase motif flexibility for gene editing in zebrafish.Nature communications · 2024Article
- Comprehensive evaluation and prediction of editing outcomes for near-PAMless adenine and cytosine base editors.Communications biology · 2024Article
- APOBEC Reporter Systems for Evaluating diNucleotide Editing Levels.The CRISPR journal · 2023Article
- Review
- Disease modeling by efficient genome editing using a near PAM-less base editor in vivo.Nature communications · 2022Article
- Precise in vivo functional analysis of DNA variants with base editing using ACEofBASEs target prediction.eLife · 2022Article
- Article
- Base editing and prime editing in laboratory animals.Laboratory animals · 2022Article
- Progress in Gene-Editing Technology of Zebrafish.Biomolecules · 2021Review
- Article
- Precise base editing for theeLife · 2021Article
- Drug Screening with Genetically Encoded Fluorescent Sensors: Today and Tomorrow.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The ease of use and robustness of genome editing by CRISPR/Cas9 has led to successful use of gene knockout zebrafish for disease modeling. However, it still remains a challenge to precisely edit the zebrafish genome to create single-nucleotide substitutions, which account for ~60% of human disease-causing mutations. Recently developed base editing nucleases provide an excellent alternate to CRISPR/Cas9-mediated homology dependent repair for generation of zebrafish with point mutations. A new set of cytosine base editors, termed BE4max and AncBE4max, demonstrated improved base editing efficiency in mammalian cells but have not been evaluated in zebrafish. Therefore, we undertook this study to evaluate their efficiency in converting C:G to T:A base pairs in zebrafish by somatic and germline analysis using highly active sgRNAs to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.